AstraZeneca

Dylan Weil '15, a scientist at AstraZeneca, credits RIT's biotechnology program for his success in developing drug potency assays for cancer immunotherapies. He highlights RIT's focus on industry preparation, advanced lab courses, and research opportunities, which shaped his career in immunology and vaccine research. Dylan's internship led to a full-time job in pharmaceutical research, and he later pursued an MS in biotechnology, integrating bioinformatics into his work at AstraZeneca. He advises RIT students to leverage experiential learning and develop diverse skills, including data science and liberal arts, for a successful career in biotechnology.

Various researchers report financial relationships with pharmaceutical companies, including Deciphera, during and outside the conduct of the study.

Experts at the Patient-Centered Oncology Care meeting discussed the impact of the Inflation Reduction Act (IRA) and Enhancing Oncology Model (EOM) on cancer care, focusing on access, innovation, and value. The IRA's shortened exclusivity periods for small molecules and changes in benefit design were highlighted, along with concerns about formulary management and drug shortages. The EOM's shift in Medicare's share of total costs and its potential to exacerbate disparities were also debated, with calls for redefining value in oncology to better support high-cost, high-value therapies.

AstraZeneca Korea launched Truqap, the first AKT inhibitor for HR+/HER2- breast cancer, targeting PIK3CA, AKT1, or PTEN mutations. Truqap, approved in April, offers new hope for patients progressing after endocrine therapy. The CAPItello-291 study showed Truqap plus fulvestrant doubled median progression-free survival to 7.3 months. Despite financial concerns over NGS costs, global guidelines recommend mutation testing for effective treatment.

Post-hoc analysis in DESTINY-Breast12 showed CNS ORR of 82.6% in patients without prior CNS therapy and 50.0% in those with prior therapy. Safety profiles of Enhertu were consistent with previous trials, with no new concerns. ILD/pneumonitis rates were 12.9% and 16.0% in patients without and with brain metastases, respectively, with most events being low grade.

Personalized medicine market to reach $900.67 Bn by 2030, driven by cancer therapies and genetic tech. North America leads, emphasizing personalized nutrition and expanding therapeutic applications.

The 'Migraine: Seven-Market Drug Forecast and Market Analysis' report, added to ResearchAndMarkets.com's offering, forecasts the migraine market in the US, France, Germany, Italy, Spain, the UK, and Japan to grow from $9.2 billion in 2023 to $16.4 billion by 2033, driven by a 6.0% CAGR. The report covers epidemiology, treatment options, unmet needs, pipeline analysis, and market competition.

India's 'BioE3' policy aims to drive biotech innovation through biomanufacturing, bio-AI hubs, and bio-foundries, focusing on precision therapeutics and biologics. Organ-on-chip technology, valued at $1.4 billion by 2032, offers a more accurate drug testing platform, reducing animal use and speeding up drug development. Investments and collaborations globally highlight the technology's potential, while India faces challenges in interdisciplinary collaboration and regulatory navigation to fully utilize this technology.

Innate Pharma reported H1 2024 financials and clinical updates, including $12.3M revenue, $38.7M operating expenses, and $102.1M cash reserves. Lacutamab, an orphan drug, showed promising results in trials and received FDA designation. The ANKET platform advanced with SAR443579 in Phase 2 and IPH6501 in clinical trials. IPH45, an ADC targeting Nectin-4, is moving to Phase 1. The company aims to address unmet oncology needs and expects clinical data in the coming years.

Aristotle's early animal dissections evolved into standard drug development practices by the late 1930s, leading to the 1938 Federal Food, Drug, and Cosmetic Act. Despite animal testing's contributions to medicine, 95% of drugs fail post-testing. Thomas Hartung's research at Johns Hopkins Center for Alternatives to Animal Testing advocates for AI and organoid cultures to replace animal tests, with some success. The FDA Modernization Act of 2023 no longer requires animal testing before clinical trials, and collaborations like CAAT's with the FDA aim to advance nonanimal testing methods. However, challenges remain in replacing animal models entirely due to technological limitations and systemic resistance.